Teva UK has announced the launch of a generic CFC-free salmeterol metered dose inhaler in the UK; the product is a suspension pMDI that delivers 25 mcg per actuation. The UK granted marketing authorization for the Neovent/Sereflo inhaler for the treatment of asthma and COPD to Neolab Limited in April 2011.
Kim Innes, Teva UK Commercial Director, commented, “We are delighted to be bringing the first generic version of this product to the UK market, and at the same time further broaden our portfolio, which is the widest of any UK generics supplier.”
Read the Teva UK press release.
Read the MHRA report.
